Ligand Pharmaceuticals Incorporated (LGND) - News Archive

In a significant move aimed at bolstering its financial health and operational oversight, Palvella Therapeutics has appointed Matthew E. Korenberg as its new Chief Financial Officer (CFO). Korenberg joins Palvella with...

In the ever-evolving landscape of biotechnology and pharmaceuticals, the ability to innovate and provide solutions that address unmet medical needs is paramount. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has ac...

Sparsentan: A Breakthrough in IgA Nephropathy Treatment and its Impact on Ligand Pharmaceuticals The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement in the treatment of Immunoglobulin A...

: The approval of Ohtuvayre (ensifentrine) by the U.S. Food and Drug Administration (FDA) marks pivotal progress in the treatment paradigm of chronic obstructive pulmonary disease (COPD). Developed by Verona Pharma plc...

In a significant leap forward for public health, Ligand Pharmaceuticals Incorporated recently announced that its pharmaceutical collaborator Merck has received approval from the U.S. Food and Drug Administration (FDA) f...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), two prominent forces in the biopharmaceutical industry, have announced a landmark $100 million royalty financing agreement. The deal, fo...

Ligand Pharmaceuticals Grants Stock Options and Units to Non-Executive Employees SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), a leading biopharmaceutical company, has recently announced the grant of n...

In an unprecedented move set to revolutionize the medical field, the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI (berdazimer topical gel, 10.3%) as a groundbreaking discovery for the treatment of mollu...